Clinically, the occurrence of IDH1/2 mutations predicts longer survival and greater sensitivity to chemotherapy; thus, IDH-mutant astrocytomas carry significantly better prognosis as compared to glioblastomas [3]. Here, IDH1 is linked to glioblastoma.